- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta T Cells Technology for Solid and Liquid Cancers | 67 | GlobeNewswire (Europe) | SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies... ► Artikel lesen | |
| 20.06. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.05. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 22.04. | CytoMed Therapeutics Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 20.03. | CytoMed enters stem cell trial for cartilage repair | 1 | Investing.com | ||
| 20.03. | CytoMed Therapeutics Limited: CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration | 402 | ACCESSWIRE | SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed proprietary... ► Artikel lesen | |
| 18.03. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies | 173 | GlobeNewswire (Europe) | SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary... ► Artikel lesen | |
| 04.03. | CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair | 149 | GlobeNewswire (Europe) | SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary... ► Artikel lesen | |
| 29.01. | CytoMed Therapeutics Limited: Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology | 615 | GlobeNewswire (Europe) | SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies... ► Artikel lesen | |
| 24.10.23 | CytoMed Therapeutics Limited: CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology | 575 | ACCESSWIRE | SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,650 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,341 | -4,21 % | Defence Therapeutics Inc.: Defence Appoints New Interim Chief Executive Officer | Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed... ► Artikel lesen | |
| GINKGO BIOWORKS | 5,610 | -1,58 % | Ginkgo Bioworks Introduces Ginkgo Automation Product Line | ||
| RECURSION PHARMACEUTICALS | 6,570 | +1,08 % | Recursion Pharmaceuticals CFO Secora Michael sells shares worth $187,228 | ||
| BEAM THERAPEUTICS | 26,330 | +7,91 % | Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) | ||
| ONCOLYTICS BIOTECH | 0,800 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter 2024 Financial Results and Operational Highlights | Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer
On track to report overall survival results... ► Artikel lesen | |
| ASSERTIO | 1,235 | -2,76 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,750 | +4,22 % | CSL And Arcturus Therapeutics Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 Vaccine | CANBERA (dpa-AFX) - Australian biotechnology company CSL Ltd. (CSL.AX, CSLLY.PK) and sa-mRNA pioneer Arcturus Therapeutics, announced Friday that Japan's Ministry of Health, Labor and Welfare... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 7,900 | +0,38 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,090 | +2,49 % | Adma biologics director sells shares worth over $166k | ||
| VIR BIOTECHNOLOGY | 8,110 | +3,18 % | Vir Biotechnology names Jason O'Byrne as CFO | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,500 | -2,65 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 13,290 | +5,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) | If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9,... ► Artikel lesen | |
| ARVINAS | 25,060 | +2,24 % | Critical Insights From Arvinas Analyst Ratings: What You Need To Know |
CYTOMED THERAPEUTICS LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOMED THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.
